Mealey's (February 18, 2021, 2:04 PM EST) -- PHILADELPHIA — A federal judge in Pennsylvania on Feb. 16 ruled that shareholders in a securities class action lawsuit against a biotechnology company and three of its senior executives have sufficiently pleaded the necessary elements of their federal securities law claims for two of three categories of misrepresentations the investors allege the defendants made regarding the manufacturing possibilities of the company’s COVID-19 coronavirus vaccine candidate and its selection for the federal government’s Operation Warp Speed program....